Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
Blood|June 17, 2016
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myelomaInger S Nijhof, Tineke Casneuf, Jeroen van Velzen, et al.
Journal of Visualized Experiments : Jove|March 20, 2018
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid LeukemiaJacqueline Cloos, Jeffrey R Harris, Jeroen J W M Janssen, et al.
Blood|August 18, 2016
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myelomaTorben Plesner, Hendrik-Tobias Arkenau, Peter Gimsing, et al.
The New England Journal of Medicine|August 27, 2015
Targeting CD38 with Daratumumab Monotherapy in Multiple MyelomaHenk M Lokhorst, Torben Plesner, Jacob P Laubach, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2017
Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with DaratumumabJakub Krejcik, Kris A Frerichs, Inger S Nijhof, et al.
The Australian and New Zealand Journal of Psychiatry|April 6, 2017
The Anorexia Nervosa Genetics Initiative: Study description and sample characteristics of the Australian and New Zealand armKatherine M Kirk, Felicity C Martin, Amy Mao, et al.
Ebiomedicine|June 28, 2023
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activityIda H Hiemstra, Kim C M Santegoets, Maarten L Janmaat, et al.
Haematologica|September 22, 2018
Daratumumab plus lenalidomide and dexamethasone <i>versus</i> lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUXMeletios A Dimopoulos, Jesus San-Miguel, Andrew Belch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2017
The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future ApplicationsKenneth C Anderson, Daniel Auclair, Gary J Kelloff, et al.
Haematologica|September 22, 2018
Daratumumab plus bortezomib and dexamethasone <i>versus</i> bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTORAndrew Spencer, Suzanne Lentzsch, Katja Weisel, et al.
Pageof 9